Cabergoline is a dopamine agonist used for prolactin disorders. It is discussed in PED communities for managing prolactin, but high cumulative doses in Parkinson's disease were linked to valve disease, and impulse-control effects are documented.
Key points
- Effective for hyperprolactinaemia in clinical settings.
- Higher cumulative doses have been associated with cardiac valvulopathy.
- Impulse-control disorders are a recognised dopamine-agonist effect.
- Products sold online under this name have not been independently verified; label identity and concentration cannot be assumed.
What the literature shows
Schade and colleagues reported increased valvular regurgitation risk with dopamine agonists, including cabergoline, in Parkinson's disease.
Studies at the lower doses used for prolactinomas have generally found less valvular risk, which highlights dose dependence.
What remains unknown
- Whether prolactin elevations in PED users require treatment at all.
- Valvular risk with intermittent recreational use.
Safety and monitoring implications
- Report compulsive behaviour changes.
- Prolactin should be measured and interpreted by a clinician, not inferred from symptoms.
Cited literature
- 1.Schade R, Andersohn F, Suissa S, et al. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine. Find on PubMed
- 2.Caputo C, Prior D, Inder WJ. (2015). The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes and Endocrinology. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedCommunity discussion of this compound is widespread, but no independently verified reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying Cabergoline in Australia: what to check first
APEDRA does not sell Cabergoline or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.